The 21 serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease in individuals 65 years of age and older, according to CDC data from 2018-2021
Results from Phase 3 trial, STRIDE-3, to be presented at World Vaccine Congress West Coast
https://finance.yahoo.com/news/merck-v116-investigational-21-valent-114500605.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.